269 related articles for article (PubMed ID: 22735804)
1. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
[TBL] [Abstract][Full Text] [Related]
2. Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy.
Wilcox RA; Flies DB; Wang H; Tamada K; Johnson AJ; Pease LR; Rodriguez M; Guo Y; Chen L
Cancer Res; 2002 Aug; 62(15):4413-8. PubMed ID: 12154048
[TBL] [Abstract][Full Text] [Related]
3. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
4. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
5. Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody.
Ju SA; Park SM; Lee SC; Kwon BS; Kim BS
Mol Cells; 2007 Aug; 24(1):132-8. PubMed ID: 17846508
[TBL] [Abstract][Full Text] [Related]
6. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.
Palazón A; Teijeira A; Martínez-Forero I; Hervás-Stubbs S; Roncal C; Peñuelas I; Dubrot J; Morales-Kastresana A; Pérez-Gracia JL; Ochoa MC; Ochoa-Callejero L; Martínez A; Luque A; Dinchuk J; Rouzaut A; Jure-Kunkel M; Melero I
Cancer Res; 2011 Feb; 71(3):801-11. PubMed ID: 21266358
[TBL] [Abstract][Full Text] [Related]
7. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.
Murillo O; Dubrot J; Palazón A; Arina A; Azpilikueta A; Alfaro C; Solano S; Ochoa MC; Berasain C; Gabari I; Pérez-Gracia JL; Berraondo P; Hervás-Stubbs S; Melero I
Eur J Immunol; 2009 Sep; 39(9):2424-36. PubMed ID: 19662633
[TBL] [Abstract][Full Text] [Related]
8. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
[TBL] [Abstract][Full Text] [Related]
9. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
Takeda K; Kojima Y; Uno T; Hayakawa Y; Teng MW; Yoshizawa H; Yagita H; Gejyo F; Okumura K; Smyth MJ
J Immunol; 2010 May; 184(10):5493-501. PubMed ID: 20400706
[TBL] [Abstract][Full Text] [Related]
11. In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.
Teschner D; Wenzel G; Distler E; Schnürer E; Theobald M; Neurauter AA; Schjetne K; Herr W
Scand J Immunol; 2011 Aug; 74(2):155-64. PubMed ID: 21517928
[TBL] [Abstract][Full Text] [Related]
12. Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.
Kurosawa S; Harada M; Matsuzaki G; Shinomiya Y; Terao H; Kobayashi N; Nomoto K
Immunology; 1995 Jun; 85(2):338-46. PubMed ID: 7642226
[TBL] [Abstract][Full Text] [Related]
13. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
14. Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites.
Sin JI; Kim H; Ahn E; Jeon YH; Park WS; Lee SY; Kwon B
Cancer Lett; 2013 Apr; 330(2):190-9. PubMed ID: 23219755
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy.
Choi BK; Kim YH; Kang WJ; Lee SK; Kim KH; Shin SM; Yokoyama WM; Kim TY; Kwon BS
Cancer Res; 2007 Sep; 67(18):8891-9. PubMed ID: 17875731
[TBL] [Abstract][Full Text] [Related]
16. Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells.
Dubrot J; Portero A; Orive G; Hernández RM; Palazón A; Rouzaut A; Perez-Gracia JL; Hervás-Stubbs S; Pedraz JL; Melero I
Cancer Immunol Immunother; 2010 Nov; 59(11):1621-31. PubMed ID: 20607237
[TBL] [Abstract][Full Text] [Related]
17. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity.
Ko E; Luo W; Peng L; Wang X; Ferrone S
Cancer Res; 2007 Aug; 67(16):7875-84. PubMed ID: 17699794
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.
Lee H; Park HJ; Sohn HJ; Kim JM; Kim SJ
J Surg Res; 2011 Jul; 169(1):e43-50. PubMed ID: 21571303
[TBL] [Abstract][Full Text] [Related]
19. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
[TBL] [Abstract][Full Text] [Related]
20. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ.
Dubrot J; Milheiro F; Alfaro C; Palazón A; Martinez-Forero I; Perez-Gracia JL; Morales-Kastresana A; Romero-Trevejo JL; Ochoa MC; Hervás-Stubbs S; Prieto J; Jure-Kunkel M; Chen L; Melero I
Cancer Immunol Immunother; 2010 Aug; 59(8):1223-33. PubMed ID: 20336294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
